Nicolino Ruperto

Scopus Publications

Environmental determinants of juvenile idiopathic arthritis: current evidence and future directions
Saverio La Bella, Alessandra Alongi, Giovanni Filocamo, Marco Cattalini, Stefano Lanni, et al.
Global Pediatrics, 2026
Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept
Vyacheslav Chasnyk, Tamas Constantin, Irina Nikishina, Brigitte Bader-Meunier, Luciana Breda, et al.
Rheumatology Oxford England, 2026
Objectives To identify predictors of clinically inactive disease (CID) and clinical remission (CR) in patients with juvenile idiopathic arthritis receiving etanercept during the 2-year, phase 3b, open-label CLIPPER study (NCT00962741) and the 8-year extension study, CLIPPER2 (NCT01421069). Methods Patients with extended oligoarthritis (2–17 years), enthesitis-related arthritis or psoriatic arthritis (each 12–17 years) were enrolled in CLIPPER/CLIPPER2. Predictors of CID (according to Juvenile Arthritis Disease Activity Score [JADAS] and JIA-ACR response criteria) and CR (≥6 months of CID) were identified using a multivariate stepwise logistic regression model. Results Two-thirds of patients met the criteria for CID at any point and 34–43% achieved CR. Height Z-score ≥0.74, age at onset ≤12 years, normal CRP levels, HLA-B27+ status, JADAS low disease activity (LDA) at 3 months and ≤4 swollen joints were predictive of JADAS CID. BMI Z-score >0.80, age at onset ≤12 years, normal CRP levels and JADAS LDA at 3 months were predictors of JIA-ACR CID. JADAS LDA at 3 months was a predictor of JADAS CR, and height Z-score >1.23, JADAS LDA at 3 months and >12 swollen joints were identified as predictors of JIA-ACR CR. Conclusion In patients with JIA treated with etanercept, early responses to treatment in line with treat-to-target recommendations, younger age, HLA-B27+ status and lower disease activity at baseline were associated with clinically inactive disease and clinical remission. Trial registration ClinicalTrials.gov IDs: CLIPPER (NCT00962741); CLIPPER2 (NCT01421069)
Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab
Athimalaipet V Ramanan, Nicolino Ruperto, Ivan Foeldvari, Gabriel Vega-Cornejo, Stuart Keller, et al.
Lancet Rheumatology, 2026
Decision Tree Analysis as a Preliminary Evidence-Based Tool for Identifying the Syndrome of Undifferentiated Recurrent Fever in Children Compared With Hereditary Recurrent Fevers and Periodic Fever, Aphthosis, Pharyngitis, and Adenitis Syndrome
Riccardo Papa, Francesca Bovis, Silvia Federici, Serena Palmeri, Marta Bustaffa, et al.
Arthritis and Rheumatology, 2026
Objective To develop evidence‐based criteria to classify patients with syndrome of undifferentiated recurrent fevers (SURF). Methods One hundred twelve patients with SURF observed in a single tertiary referral center were analyzed. Patients with genetically confirmed hereditary recurrent fever (HRF) or with periodic fever, aphthosis, pharyngitis, and adenitis (PFAPA) syndrome already analyzed for the Eurofever classification criteria were used as disease controls. A decision tree approach was tested by randomly splitting the available data in a training set and in an internal test set. An alternative model using a classical regression model was also analyzed. An external validation for both approaches was performed on 123 patients recruited from four other centers. Results The decision tree model integrating clinical and genetic data identified 91% of patients with SURF. A decision tree model based solely on clinical variables identified up to 88% of patients with SURF. The logistic regression model including genetic tests exhibited an overall accuracy of 89.2% (95% confidence interval [CI] 81.1–94.7). In contrast, the logistic regression model exclusively based on clinical manifestations displayed an overall accuracy of 66.7% (95% CI 56.1–76.1). When the classification criteria including genetic tests were applied to the external validation cohort, the model demonstrated a strong discriminative power, with areas under the receiver operating characteristic curve of 96.3% using the decision tree model and 88.0% with the logistic regression model. Conclusion The study shows the possibility of achieving evidence‐based criteria that can classify SURF at least with respect to the main HRF and PFAPA syndrome and may be considered as a preliminary tool for the enrollment of more homogeneous cohorts of patients in future studies.
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, et al.
Arthritis and Rheumatology, 2026
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in patients with JIA. In the open‐label phase (part 1; weeks 0–18), patients received body weight–based doses of tofacitinib. During the double‐blind phase (part 2; weeks 18–44), responders (per JIA‐American College of Rheumatology 30 response criteria) were randomized 1:1 to continue tofacitinib or switch to placebo for up to 26 weeks. Assessed PROs included the validated parent and/or legal guardian versions of the Childhood Health Assessment Questionnaire for evaluation of disability, arthritis pain, overall well‐being, and the Child Health Questionnaire (CHQ). Results Overall, 225 patients were enrolled and received open‐label tofacitinib in part 1, and 173 patients were randomized in part 2. During part 1, least‐squares (LS) mean (SE) disability, arthritis pain, and overall well‐being scores numerically improved from mean 1.04 (SE 0.05), mean 5.53 (SE 0.20), and mean 5.07 (SE 0.20) at baseline to mean 0.57 (SE 0.05), mean 2.46 (SE 0.18), and mean 2.47 (SE 0.18) at week 18, respectively. LS mean (SE) CHQ physical summary and psychological summary scores numerically improved from mean 29.51 (SE 1.15) and mean 47.24 (SE 0.85) at baseline to mean 42.70 (SE 0.98) and mean 51.53 (SE 0.80) at week 18, respectively. Improvements were generally maintained to week 44 in part 2. Conclusion Tofacitinib improved a range of PROs in patients with JIA, suggesting potential HRQoL benefits.
Predictive value for intravenous immunoglobulin resistance of Kobayashi and Kawanet scores in 722 children with Kawasaki disease across diverse ethnic backgrounds (KIWI study): an international cohort study
Maria Vincenza Mastrolia, Vignesh Pandiarajan, Marco Cattalini, Andrea Taddio, Stefania Vergnano, et al.
Eclinicalmedicine, 2026
Sex differences in clinical and imaging characteristics of axial juvenile spondyloarthritis
Adam S Mayer, Rui Xiao, Timothy G Brandon, Pamela F Weiss, Amita Aggarwal, et al.
Rheumatology, 2026
Objectives The impact of biologic sex in axial juvenile spondyloarthritis (axJSpA) is unknown. We assessed whether biologic sex is associated with disease manifestations, patient-reported outcomes, or characteristic sacroiliac joint (SIJ) MRI lesions in a large cohort of youths with classified axJSpA. Methods This international multicentre cross-sectional study included youths aged &lt;18 years with physician-diagnosed juvenile spondyloarthritis and fulfilling the classification criteria for axJSpA. Clinical and SIJ MRI data were available from the time axial disease was first diagnosed and were compared between males and females using Pearson’s chi-squared and Wilcoxon rank-sum tests, as appropriate. Multivariable logistic regression evaluated the association of sex with inflammatory and structural MRI lesions typical of axial disease. Results Among the 143 patients included, 67.1% were male. Males had significantly greater HLA-B27 positivity, hip/groin stiffness and inflammatory marker elevation. There were no differences in peripheral arthritis, enthesitis or patient-reported outcomes. On SIJ MRI, males had significantly higher odds of unequivocal inflammatory lesions (OR 4.86, 95% CI 1.37–17.32), bone marrow oedema (OR 4.13, 95% CI 1.17–14.62) and pelvic enthesitis (OR 5.23, 95% CI 1.39–19.61) compared with females, but no differences in structural lesions were found. Conclusion In a large multicentre axJSpA cohort, males were significantly more likely to have clinical and MRI features of inflammatory sacroiliitis at the time axial disease was first diagnosed. Future trials in axJSpA should strongly consider stratification by sex in their design.
Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting
Pamela F. Weiss, Nicolino Ruperto, Erhard Quebe-Fehling, Alexis Shew, Luminita Pricop, et al.
Journal of Rheumatology, 2026
Objective To investigate the validity of the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) in children with enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (jPsA) in a prospective clinical trial setting. Methods JUNIPERA ( ClinicalTrials.gov : NCT03031782 ) is a phase III, placebo-controlled withdrawal study investigating the safety and efficacy of secukinumab in children with ERA and jPsA. After 12 weeks of open-label treatment with secukinumab, patients were randomized 1:1 to secukinumab or placebo until disease flare or week 52. JSpADA validity was assessed using 3 criteria: convergent validity (Spearman correlation) at week 12 with the Juvenile Arthritis Disease Activity Score in 10 joints (JADAS10), clinical JADAS10 (cJADAS10), and physician global assessment of disease activity (PGA); discriminatory validity at week 12 among patients with active or inactive disease and juvenile idiopathic arthritis American College of Rheumatology response criteria; and responsiveness to change in clinical disease activity from weeks 12 to 52. Results At week 12, mean (SD) JSpADA scores showed moderate to good correlation with JADAS10, cJADAS10, and PGA scores (all Spearman ρ > 0.4) and were higher among patients with active vs inactive disease (1.8 [1.3] vs 0.5 [0.8], P < 0.001). Patients with improved disease activity from weeks 12 to 52 had greater improvements in JSpADA than patients with worsening disease (−0.8 [1.1] vs 0.4 [1.0], P < 0.001); patients with stable disease had minimal change in JSpADA (−0.1 [0.5]). Validity results were similar for ERA and jPsA. Conclusion These results validate JSpADA as a disease activity measure for children with ERA and jPsA in a prospective clinical trial setting.
What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?
Ivan Foeldvari, Ameenat Solebo, Sheila T. Angeles-Han, Agnes Galbo Brost, Joke de Boer, et al.
Expert Review of Clinical Immunology, 2026
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
Hermine I. Brunner, Mittermayer Santiago, Beth Gottlieb, Sheila K. Oliveira, Pooja Patel, et al.
Annals of the Rheumatic Diseases, 2026
Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures
Didem Saygin, Matthew Diller, Varsha Surampudi, Mark Bodkin, Payam Noroozi Farhadi, et al.
Arthritis Care and Research, 2026
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world
Roberta Naddei, Marco Burrone, Francesca Ridella, Yosef Uziel, Maria Trachana, et al.
Pediatric Rheumatology, 2025
Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial
Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud‐Mendoza, Alberto Spindler, et al.
Acr Open Rheumatology, 2025
Erratum: Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study (The Journal of rheumatology (2024) 51 11 DOI: 10.3899/jrheum.2024-0298.)
Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, et al.
Journal of Rheumatology, 2025
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial
Alessandro Consolaro, Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud-Mendoza, et al.
Journal of Rheumatology, 2025
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force
Veronika Rypdal, Hermine I. Brunner, Brian M. Feldman, Nicolino Ruperto, Amita Aggarwal, et al.
Annals of the Rheumatic Diseases, 2025
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis?
Pamela F. Weiss, Timothy G. Brandon, Amita Aggarwal, Ruben Burgos‐Vargas, Robert A. Colbert, et al.
Arthritis Care and Research, 2025
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study
Caterina Matucci-Cerinic, Anna Attico, Clara Malattia, Alessandro Consolaro, Silvia Rosina, et al.
Rheumatology, 2025
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study
Marta Bustaffa, Saverio La Bella, Yagmur Bayindir, Gayane Amaryan, Romina Gallizzi, et al.
Journal of Autoimmunity, 2025
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction
Esraa Eloseily, Alex Pickering, Sanjeev Dhakal, Nicolino Ruperto, Hermine I. Brunner, et al.
Arthritis Care and Research, 2025
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus
Maarit Tarkiainen, Erin Balay‐Dustrude, Alessandro Consolaro, Esi M. Morgan, Nicolino Ruperto, et al.
Arthritis Care and Research, 2025
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score
Roberta Naddei, Francesca Ridella, Francesca Bovis, Chiara Trincianti, Ilia Avrusin, et al.
Rheumatology, 2025
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis
Adam Mayer, Timothy G. Brandon, Amita Aggarwal, Ruben Burgos-Vargas, Robert A. Colbert, et al.
Journal of Rheumatology, 2025
New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on paediatric drug development
Roberto De Lisa, Fernando de Andres-Trelles, Ralph Bax, Sara Galluzzo, Brian Alward, et al.
Frontiers in Medicine, 2025
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project
Francesco Baldo, Remco G A Erkens, Mao Mizuta, Greta Rogani, Federica Lucioni, et al.
Rheumatology, 2025
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach
Caterina Matucci-Cerinic, Helene Palluy, Sulaiman M Al-Mayouf, Paul A Brogan, Luca Cantarini, et al.
Rheumatology, 2024
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis
Jelena Vojinović, Ivan Foeldvari, Joke Dehoorne, Violeta Panaviene, Gordana Susic, et al.
Rheumatology and Therapy, 2024
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis
Ekemini A. Ogbu, Hermine I. Brunner, Esraa Eloseily, Yonatan Butbul Aviel, Kabita Nanda, et al.
Arthritis Care and Research, 2024
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis
Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, et al.
Arthritis Research and Therapy, 2024
Correction to: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis (Arthritis Research & Therapy, (2024), 26, 1, (125), 10.1186/s13075-024-03347-0)
Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, et al.
Arthritis Research and Therapy, 2024
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis
Pamela F. Weiss, Timothy G. Brandon, Amita Aggarwal, Ruben Burgos‐Vargas, Robert A. Colbert, et al.
Arthritis and Rheumatology, 2024
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study
Hermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, et al.
Journal of Rheumatology, 2024
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Hermine I Brunner, Jonathan D Akikusa, Eslam Al-Abadi, John F Bohnsack, Alina Lucica Boteanu, et al.
Annals of the Rheumatic Diseases, 2024
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis
Hermine I Brunner, Nicolino Ruperto, Athimalaipet V Ramanan, Gerd Horneff, Kirsten Minden, et al.
Rheumatology United Kingdom, 2024
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry
Daniel J Lovell, Nikolay Tzaribachev, Michael Henrickson, Gabriele Simonini, Thomas A Griffin, et al.
Rheumatology United Kingdom, 2024
The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C
Roberta Caorsi, Alessandro Consolaro, Camilla Speziani, Betul Sozeri, Kadir Ulu, et al.
Journal of Autoimmunity, 2024
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry
Yulia Vyzhga, Joost Frenkel, Antonella Insalaco, Jordi Anton, Isabelle Koné-Paut, et al.
Journal of Clinical Immunology, 2024
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study
Ana Isabel Rebollo-Giménez, Silvia Rosina, Valentina Natoli, Marco Burrone, Patrizia Barone, et al.
Clinical and Experimental Rheumatology, 2024
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index
Silvia Rosina, Alessandro Consolaro, Angela Pistorio, Ana Rebollo-Giménez, Claudia Bracaglia, et al.
Rmd Open, 2024
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis
Jelena Vojinović, Ivan Foeldvari, Joke Dehoorne, Violeta Panaviene, Gordana Susic, et al.
Rheumatology United Kingdom, 2024
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
Gerd Horneff, Kirsten Minden, Catherine Rolland, Ana C. Hernandez Daly, Cecilia Borlenghi, et al.
Pediatric Rheumatology, 2023
Breaking down the fences among registries on autoinflammatory diseases: the E-Merge project
Y. Vyzhga, V. Hentgen, R. Caorsi, H. Wittkowski, M. Hofer, et al.
Orphanet Journal of Rare Diseases, 2023
Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry
Joeri W. van Straalen, Laurie Baas, Gabriella Giancane, Lyudmila Grebenkina, Jurgen Brunner, et al.
Pediatric Rheumatology, 2023
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings
Ivan Foeldvari, Kathryn S. Torok, Jordi Anton, Michael Blakley, Tamás Constantin, et al.
Arthritis Care and Research, 2023
Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)
Athimalaipet V. Ramanan, Neena Modi, Saskia N. de Wildt, Beate Aurich, Sophia Bakhtadze, et al.
Pediatric Research, 2023
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis
Ping Wu, Chunlin Huang, Pei‐Fen Liao, Nicolino Ruperto, Huasong Zeng
International Journal of Rheumatic Diseases, 2023
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept
Hermine I. Brunner, Nikolay Tzaribachev, Ingrid Louw, Inmaculada Calvo Penades, Francisco Avila‐Zapata, et al.
Arthritis Care and Research, 2023
Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles
Didem Saygin, Hanna Kim, Christian Douglas, Brian Erman, Jesse Wilkerson, et al.
Rheumatology United Kingdom, 2023
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles
Hanna Kim, Didem Saygin, Christian Douglas, Jesse Wilkerson, Brian Erman, et al.
Rheumatology United Kingdom, 2023
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way
Maria Backström, Maarit Tarkiainen, Beth S Gottlieb, Chiara Trincianti, Tingting Qiu, et al.
Rheumatology United Kingdom, 2023
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome
Anna M. Gerritsma, Diana Sutera, Luca Cantarini, Marco Cattalini, Helen J. Lachmann, et al.
Clinical and Experimental Rheumatology, 2023
Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials
Nicolino Ruperto, Daniel J. Lovell, Alberto Berman, Jordi Anton, Diego O. Viola, et al.
Journal of Rheumatology, 2023
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
Athimalaipet V Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, et al.
Lancet, 2023
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study
Nicolino Ruperto, Daniel J. Lovell, Alberto Berman, Francisco Ávila‐Zapata, Gerd Horneff, et al.
Arthritis Care and Research, 2023
Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study
Mario Sestan, Nastasia Kifer, Betul Sozeri, Ferhat Demir, Kadir Ulu, et al.
Seminars in Arthritis and Rheumatism, 2023
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA
Hermine I Brunner, Aisha Vadhariya, Christina Dickson, Wallace Crandall, Casey Kar-Chan Choong, et al.
Lupus Science and Medicine, 2023
Validity and Reliability of Four Parent/Patient–Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring
E. H. Pieter van Dijkhuizen, Francesca Ridella, Roberta Naddei, Chiara Trincianti, Ilia Avrusin, et al.
Arthritis Care and Research, 2023
Corrigendum to The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort (Seminars in Arthritis and Rheumatism (2022) 52, (S0049017222000087), (10.1016/j.semarthrit.2022.151957)): <[ Seminars in Arthritis and Rheumatism Volume 52, 151957]>
Marta Bustaffa, Isabelle Koné-Paut, Seza Ozen, Gayane Amaryan, Efimia Papadopoulou-Alataki, et al.
Seminars in Arthritis and Rheumatism, 2023
Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
Joeri W. van Straalen, Lianne Kearsley‐Fleet, Jens Klotsche, Sytze de Roock, Kirsten Minden, et al.
Arthritis and Rheumatology, 2023
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: A randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
Hermine I Brunner, Ivan Foeldvari, Ekaterina Alexeeva, Nuray Aktay Ayaz, Inmaculada Calvo Penades, et al.
Annals of the Rheumatic Diseases, 2023
Juvenile idiopathic arthritis
Alberto Martini, Daniel J. Lovell, Salvatore Albani, Hermine I. Brunner, Kimme L. Hyrich, et al.
Nature Reviews Disease Primers, 2022
Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Ekaterina Alexeeva, Elena Koskova, et al.
Pediatric Rheumatology, 2022
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the “comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS” (STARS) trial
Marco Burrone, Marta Mazzoni, Roberta Naddei, Angela Pistorio, Maddalena Spelta, et al.
Pediatric Rheumatology, 2022
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
Joeri W. van Straalen, Sytze de Roock, Gabriella Giancane, Alessandro Consolaro, Marite Rygg, et al.
Pediatric Rheumatology, 2022
Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey
Francesca Minoia, Federica Lucioni, Merav Heshin-Bekenstein, Sebastiaan Vastert, Christoph Kessel, et al.
Frontiers in Pediatrics, 2022
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist
Micol Romano, Z. Serap Arici, David Piskin, Sara Alehashemi, Daniel Aletaha, et al.
Arthritis and Rheumatology, 2022
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist
Micol Romano, Z Serap Arici, David Piskin, Sara Alehashemi, Daniel Aletaha, et al.
Annals of the Rheumatic Diseases, 2022
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: A collaborative analysis of 3 JIA registries
Lianne Kearsley-Fleet, Jens Klotsche, Joeri W van Straalen, Wendy Costello, Gianfranco D’Angelo, et al.
Rheumatology United Kingdom, 2022
Tofacitinib for juvenile idiopathic arthritis – Authors' reply
Nicolino Ruperto, Hermine I Brunner, Holly B Posner, Irina Lazariciu, Alberto Martini, et al.
Lancet, 2022
Reply
Nicolino Ruperto, Alberto Martini, Angela Pistorio, for the Paediatric Rheumatology International Trials Organisation
Arthritis and Rheumatology, 2022
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
Joeri W van Straalen, Roline M Krol, Gabriella Giancane, Violeta Panaviene, Laura Marinela Ailioaie, et al.
Rheumatology United Kingdom, 2022
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry
Gabriella Giancane, Riccardo Papa, Sebastiaan Vastert, Francesca Bagnasco, Joost F. Swart, et al.
Journal of Rheumatology, 2022
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Athimalaipet V. Ramanan, Neena Modi, Saskia N. de Wildt, c4c Learning from COVID-19 Group, Beate Aurich, et al.
Pediatric Research, 2022
Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
Alessandra Alongi, Gabriella Giancane, Roberta Naddei, Valentina Natoli, Francesca Ridella, et al.
Rmd Open, 2022
The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort
Marta Bustaffa, Isabelle Koné-Paut, Seza Ozen, Gayane Amaryan, Efimia Papadopoulou-Alataki, et al.
Seminars in Arthritis and Rheumatism, 2022
Emerging therapies for juvenile arthritis: agents in early clinical trials
Silvia Rosina, Gabriella Giancane, Nicolino Ruperto
Expert Opinion on Investigational Drugs, 2022
Response to: 'Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?' by Fayand et al
Marco Gattorno, Michael Hofer, Federica Vanoni, Silvia Federici, Luca Cantarini, et al.
Annals of the Rheumatic Diseases, 2022
Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis
Gabriella Giancane, Chiara Campone, Maria Francesca Gicchino, Alessandra Alongi, Cecilia Bava, et al.
Arthritis Care and Research, 2021
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
Nicolino Ruperto, Hermine I Brunner, Olga Synoverska, Tracy V Ting, Carlos Abud Mendoza, et al.
Lancet, 2021
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis
Chiara Trincianti, Evert Hendrik Pieter Van Dijkhuizen, Alessandra Alongi, Marta Mazzoni, Joost F. Swart, et al.
Arthritis and Rheumatology, 2021
“To Randomize, or Not to Randomize, That is the Question”
Nicolino Ruperto, Alberto Martini, Angela Pistorio, for the Paediatric Rheumatology International Trials Organisation
Arthritis and Rheumatology, 2021
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Nicolino Ruperto, Hermine I Brunner, Athimalaipet V Ramanan, Gerd Horneff, Rubén Cuttica, et al.
Rheumatology United Kingdom, 2021
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
Nicolino Ruperto, Hermine I Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, et al.
Rheumatology United Kingdom, 2021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: An across-study comparison
Hermine I Brunner, Carlos Abud-Mendoza, Masaaki Mori, Clarissa A Pilkington, Reema Syed, et al.
Rmd Open, 2021
Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis
Hermine I. Brunner, Chen Chen, Francesca Bovis, Fabrizio De Benedetti, Graciela Espada, et al.
Arthritis Care and Research, 2021
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial
Paul A. Brogan, Barbara Arch, Helen Hickey, Jordi Anton, Este Iglesias, et al.
Arthritis and Rheumatology, 2021
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study
Marta Bustaffa, Francesca Mazza, Diana Sutera, Maria Domenica Carrabba, Maria Alessio, et al.
Journal of Allergy and Clinical Immunology in Practice, 2021
Absence of association between abatacept exposure and initial infection in patients with juvenile idiopathic arthritis
Nicolino Ruperto, Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega-Cornejo, Ingrid Louw, et al.
Journal of Rheumatology, 2021
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
Joeri W van Straalen, Gabriella Giancane, Yasmine Amazrhar, Nikolay Tzaribachev, Calin Lazar, et al.
Rheumatology United Kingdom, 2021
Development and testing of reduced versions of the manual muscle test-8 in juvenile dermatomyositis
Silvia Rosina, Giulia C. Varnier, Angela Pistorio, Clarissa Pilkington, Susan Maillard, et al.
Journal of Rheumatology, 2021
Biological classification of childhood arthritis: roadmap to a molecular nomenclature
Peter A. Nigrovic, Robert A. Colbert, V. Michael Holers, Seza Ozen, Nicolino Ruperto, et al.
Nature Reviews Rheumatology, 2021
Publisher Correction: Biological classification of childhood arthritis: roadmap to a molecular nomenclature (Nature Reviews Rheumatology, (2021), 17, 5, (257-269), 10.1038/s41584-021-00590-6)
Peter A. Nigrovic, Robert A. Colbert, V. Michael Holers, Seza Ozen, Nicolino Ruperto, et al.
Nature Reviews Rheumatology, 2021
Outcome Scores in Pediatric Rheumatology
Gabriella Giancane, Silvia Rosina, Alessandro Consolaro, Nicolino Ruperto
Current Rheumatology Reports, 2021
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial
Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Rubén Cuttica, Vladimir Keltsev, et al.
Arthritis and Rheumatology, 2021
INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry
Riccardo Papa, Thirusha Lane, Kirsten Minden, Isabelle Touitou, Luca Cantarini, et al.
Journal of Allergy and Clinical Immunology in Practice, 2021
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study
Pierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, Vyacheslav Chasnyk, Nico Wulffraat, et al.
Arthritis and Rheumatology, 2021
Some clarifications on the new classification criteria for recurrent fevers
Marco Gattorno, Michael Hofer, Silvia Federici, Federica Vanoni, Nicolino Ruperto
Seminars in Arthritis and Rheumatism, 2020
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine I. Brunner, Robert Wong, Marleen Nys, Tzuyung D. Kou, Alyssa Dominique, et al.
Pediatric Drugs, 2020
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study
Hermine I. Brunner, Pierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, Isabelle Koné‐Paut, et al.
Arthritis and Rheumatology, 2020
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis
Jessica Tibaldi, Angela Pistorio, Elena Aldera, Laura Puzone, Yasser El Miedany, et al.
Rheumatology United Kingdom, 2020
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial
Hermine I Brunner, Carlos Abud-Mendoza, Diego O Viola, Inmaculada Calvo Penades, Deborah Levy, et al.
Annals of the Rheumatic Diseases, 2020
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results
Hermine I. Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, et al.
Arthritis Care and Research, 2020
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: Post hoc radiographic analysis from two randomized controlled trials
Clara Malattia, Nicolino Ruperto, Silvia Pederzoli, Elena Palmisani, Angela Pistorio, et al.
Arthritis Research and Therapy, 2020
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
Daniel J Lovell, Hermine I Brunner, Andreas O Reiff, Lawrence Jung, Katerina Jarosova, et al.
Rmd Open, 2020
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Gabriella Giancane, Joost F. Swart, Elio Castagnola, Andreas H. Groll, et al.
Arthritis Research and Therapy, 2020
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept
for the Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation, Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega Cornejo, Rik Joos, et al.
Pediatric Rheumatology, 2020
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study
Ellen Nordal, Angela Pistorio, Marite Rygg, Gabriella Giancane, Mohamad Maghnie, et al.
Arthritis Care and Research, 2020
Towards European harmonisation of healthcare for patients with rare immune disorders: Outcome from the ERN RITA registries survey
on behalf of ERN RITA Council, Riccardo Papa, Andrew Cant, Christoph Klein, Mark A. Little, et al.
Orphanet Journal of Rare Diseases, 2020
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases
Nienke M Ter Haar, Charlotte Eijkelboom, Luca Cantarini, Riccardo Papa, Paul A Brogan, et al.
Annals of the Rheumatic Diseases, 2019
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
Majed Khraishi, Brad Millson, John Woolcott, Heather Jones, Lisa Marshall, et al.
Pediatric Rheumatology, 2019
Treatment of juvenile idiopathic arthritis: what’s new?
Gabriella Giancane, Nicolino Ruperto
Current Opinion in Rheumatology, 2019
Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis
Manuela Pardeo, Jianmei Wang, Nicolino Ruperto, Ekaterina Alexeeva, Vyacheslav Chasnyk, et al.
Journal of Rheumatology, 2019
Establishing an updated core domain set for studies in juvenile idiopathic arthritis: A report from the OMERACT 2018 JIA workshop
Esi M. Morgan, Jane E. Munro, Jennifer Horonjeff, Ben Horgan, Beverley Shea, et al.
Journal of Rheumatology, 2019
Classification criteria for autoinflammatory recurrent fevers
Marco Gattorno, Michael Hofer, Silvia Federici, Federica Vanoni, Francesca Bovis, et al.
Annals of the Rheumatic Diseases, 2019
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis
Silvia Rosina, Alessandro Consolaro, Pieter van Dijkhuizen, Angela Pistorio, Giulia Camilla Varnier, et al.
Rheumatology United Kingdom, 2019
The European network for care of children with paediatric rheumatic diseases: Care across borders
Pavla Dolezalova, Jordi Anton, Tadej Avcin, Michael W Beresford, Paul A Brogan, et al.
Rheumatology United Kingdom, 2019
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Ivan Foeldvari, Tamàs Constantin, Jelena Vojinović, Gerd Horneff, et al.
Arthritis Research and Therapy, 2019
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Gabriella Giancane, Claudio Lavarello, Angela Pistorio, Sheila K. Oliveira, et al.
Pediatric Rheumatology, 2019
American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus
Hermine I. Brunner, Michael J. Holland, Michael W. Beresford, Stacy P. Ardoin, Simone Appenzeller, et al.
Arthritis Care and Research, 2019
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
Alessandro Consolaro, Gabriella Giancane, Alessandra Alongi, Evert Hendrik Pieter van Dijkhuizen, Amita Aggarwal, et al.
Lancet Child and Adolescent Health, 2019
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind
Christiaan Scott, Mercedes Chan, Waheba Slamang, Lawrence Okong’o, Ross Petty, et al.
Clinical Rheumatology, 2019
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities
Hermine I Brunner, Alberto Martini, Daniel J Lovell, Nicolino Ruperto
Annals of the Rheumatic Diseases, 2019
Toward new classification criteria for juvenile idiopathic arthritis: First steps, pediatric rheumatology international trials organization international consensus
Alberto Martini, Angelo Ravelli, Tadej Avcin, Michael W. Beresford, Ruben Burgos-Vargas, et al.
Journal of Rheumatology, 2019
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis
Francesca Minoia, Francesca Bovis, Sergio Davì, AnnaCarin Horne, Michel Fischbach, et al.
Annals of the Rheumatic Diseases, 2019
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: Combined data of more than 15,000 patients from Pharmachild and national registries
for the Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry, Joost Swart, Gabriella Giancane, Gerd Horneff, Bo Magnusson, et al.
Arthritis Research and Therapy, 2018
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto, Hermine I Brunner, Pierre Quartier, Tamàs Constantin, Nico M Wulffraat, et al.
Annals of the Rheumatic Diseases, 2018
Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis
Clinical and Experimental Rheumatology, 2018
Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus
Michael J. Holland, Michael W. Beresford, Brian M. Feldman, Jennifer Huggins, Ximena Norambuena, et al.
Arthritis Care and Research, 2018
Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care
Giulia Camilla Varnier, Silvia Rosina, Cristina Ferrari, Angela Pistorio, Alessandro Consolaro, et al.
Arthritis Care and Research, 2018
Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial
Kamal N. Bharucha, Hermine I. Brunner, Inmaculada Calvo Penadés, Irina Nikishina, Nadina Rubio-Pérez, et al.
Journal of Rheumatology, 2018
Erratum: The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry (Rheumatology (Oxford, England) (2018))
Hermann Girschick, Martina Finetti, Francesca Orlando, Susanne Schalm, Antonella Insalaco, et al.
Rheumatology Oxford England, 2018
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: A series of 486 cases from the Eurofever international registry
Hermann Girschick, Martina Finetti, Francesca Orlando, Susanne Schalm, Antonella Insalaco, et al.
Rheumatology United Kingdom, 2018
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Alessandro Consolaro, Francesca Bovis, Angela Pistorio, Rolando Cimaz, et al.
Rheumatology International, 2018
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study
Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega‐Cornejo, Ingrid Louw, Alberto Berman, et al.
Arthritis and Rheumatology, 2018
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus
Hermine I. Brunner, Michael Holland, Michael W. Beresford, Stacy P. Ardoin, Simone Appenzeller, et al.
Arthritis Care and Research, 2018
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force
Angelo Ravelli, Alessandro Consolaro, Gerd Horneff, Ronald M Laxer, Daniel J Lovell, et al.
Annals of the Rheumatic Diseases, 2018
Current and future perspectives in the management of juvenile idiopathic arthritis
Nicolino Ruperto, Alberto Martini
Lancet Child and Adolescent Health, 2018
Update on outcome assessment in myositis
Lisa G. Rider, Rohit Aggarwal, Pedro M. Machado, Jean-Yves Hogrel, Ann M. Reed, et al.
Nature Reviews Rheumatology, 2018
Correction: A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry [Pediatr Rheumatol., 15, (2017) (84)] DOI: 10.1186/s12969-017-0213-x
Romina Gallizzi, Caterina Pidone, Luca Cantarini, Martina Finetti, Marco Cattalini, et al.
Pediatric Rheumatology, 2018
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA)
for Eurofever and the Paediatric Rheumatology International Trials Organisation (PRINTO), Federica Vanoni, Silvia Federici, Jordi Antón, Karyl S. Barron, et al.
Pediatric Rheumatology, 2018
Preface
For the Epidemiology, treatment and Outcome of Childhood Arthritis (EPOCA) Project, Angelo Ravelli, For the Paediatric Rheumatology International Trials Organisation (PRINTO), Alessandro Consolaro, Alberto Martini, et al.
Rheumatology International, 2018
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Ximena Norambuena, Alessandro Consolaro, Francesca Bovis, Nicolino Ruperto
Rheumatology International, 2018
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Jose Antonio Melo-Gomes, Filipa Oliveira-Ramos, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Zoilo Morel Ayala, Ruben Burgos-Vargas, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Maria Ekelund, Lillemor Berntson, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Cristina Herrera Mora, Stella Maris Garay, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Chris Pruunsild, Jaanika Ilisson, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Maka Ioseliani, Karaman Pagava, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Yaryna Boyko, Ihor Hrytsiuk, Alessandro Consolaro, Francesca Bovis, et al.
Rheumatology International, 2018
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Raul Gutierrez-Suarez, Ruben Burgos-Vargas, Gabriela Burgos-Martinez, Alessandro Consolaro, et al.
Rheumatology International, 2018
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organization (PRINTO), Sulaiman M. Al-Mayouf, Ashwaq AlE’ed, Mohammed Muzaffer, Alessandro Consolaro, et al.
Rheumatology International, 2018
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Maya-Feriel Aiche, Hachemi Djoudi, Sulaiman Al-Mayouf, Alessandro Consolaro, et al.
Rheumatology International, 2018
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Clara Malagon, Angela Catalina Mosquera Pongutà, Jaime De Inocencio, Alessandro Consolaro, et al.
Rheumatology International, 2018
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Neil Martin, Joyce Davidson, Catriona Anderson, Alessandro Consolaro, et al.
Rheumatology International, 2018
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Veronika Vargová, Tomáš Dallos, Monika Leščišinová, Pavol Mrážik, et al.
Rheumatology International, 2018
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Safiya Al-Abrawi, Sulaiman M. Al-Mayouf, Reem Abdwani, Eiman Ibrahim Abdel Aziz Abdalla, et al.
Rheumatology International, 2018
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Yosef Uziel, Gilad Sherman, Noa Rabinowicz, Liora Harel, et al.
Rheumatology International, 2018
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Joke Dehoorne, Rik Joos, Carine Wouters, Joost F. Swart, et al.
Rheumatology International, 2018
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Lidia Rutkowska-Sak, Elzbieta Smolewska, Agnieszka Zygmunt, Malgorzata Kwiatkowska, et al.
Rheumatology International, 2018
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Skirmante Rusoniene, Violeta Panaviene, Kristina Jankauskaitė, Diana Cvilik, et al.
Rheumatology International, 2018
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Ingrida Rumba-Rozenfelde, Ieva Saulite, Ance Rubene, Danute Razuka-Ebela, et al.
Rheumatology International, 2018
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Amita Aggarwal, Raju Khubchandani, Sujata Sawhney, Mujeeb T. Rahman, et al.
Rheumatology International, 2018
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Nahid Shafaie, Vahid Ziaee, Yahya Aghighi, Seyed Reza Raees Karami, et al.
Rheumatology International, 2018
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Paivi Miettunen, Gaëlle Chédeville, Joanna Mazza, Michael Hofer, et al.
Rheumatology International, 2018
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Yasser El Miedany, Dalia M. E. El Mikkawy, Sally S. Youssef, Maha El Gaafary, et al.
Rheumatology International, 2018
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Natasa Toplak, Tadej Avcin, Maja Camernik, Mateja Hren, et al.
Rheumatology International, 2018
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Irina Nikishina, Ekaterina Alexeeva, Svetlana Arsenyeva, Svetlana Salugina, et al.
Rheumatology International, 2018
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Soamarat Vilaiyuk, Sirisucha Soponkanaporn, Butsabong Lerkvaleekul, Tapanee Pipatkullachart, et al.
Rheumatology International, 2018
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Daniel J. Lovell, Hermine I. Brunner, Sarah Ringold, Pamela F. Weiss, et al.
Rheumatology International, 2018
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Dimitrina Mihaylova, Boriana Varbanova, Stefan Stefanov, Albena Teltcharova-Mihaylovska, et al.
Rheumatology International, 2018
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Soad Hashad, Mabruka Ahmed Zletni, Sulaiman M. Al-Mayouf, Hala Etayari, et al.
Rheumatology International, 2018
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Christiaan Scott, Lawrence Okong’o, Nicky Brice, Sarah Murless, et al.
Rheumatology International, 2018
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Pavla Doležalová, Marek Bohm, Lenka Linková, Melánia Saifrídová, et al.
Rheumatology International, 2018
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Susan Nielsen, Troels Herlin, Anne Estmann Christensen, Marek Zak, et al.
Rheumatology International, 2018
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Gordana Susic, Jelena Vojinovic, Gordana Vijatov-Djuric, Dejan Stevanovic, et al.
Rheumatology International, 2018
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Michael Hofer, Annette von Scheven-Gête, Matthieu Santos, Pierre Quartier, et al.
Rheumatology International, 2018
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Berit Flato, Marite Rygg, Ellen Berit Nordal, Mona Røisland, et al.
Rheumatology International, 2018
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Nico Wulffraat, Sylvia Kamphuis, Joost F. Swart, Sebastiaan Vastert, et al.
Rheumatology International, 2018
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Taciana A. Pedrosa Fernandes, Claudia Saad Magalhães, Sheila Knupp Oliveira, Flavio Sztajnbok, et al.
Rheumatology International, 2018
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Pekka Lahdenne, Kristiina Aalto, Katariina Rebane, Paula Vahasalo, et al.
Rheumatology International, 2018
The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Călin Lazăr, Nicolae Iagăru, Constantin Ailioaie, Laura-Marinela Ailioaie, et al.
Rheumatology International, 2018
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Francesca Bovis, Alessandro Consolaro, Angela Pistorio, Marco Garrone, et al.
Rheumatology International, 2018
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Ilonka Orbán, Tamás Constantin, Beáta Dérfalvi, Krisztina Sevcic, et al.
Rheumatology International, 2018
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Polyxeni Pratsidou-Gertsi, Maria Trachana, Florence Kanakoudi-Tsakalidou, Elena Tsitsami, et al.
Rheumatology International, 2018
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Stella Maris Garay, Ruben Cuttica, Maria Martha Katsicas, Graciela Espada, et al.
Rheumatology International, 2018
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Pierre Quartier, Michael Hofer, Carine Wouters, Thi Thanh Thao Truong, et al.
Rheumatology International, 2018
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Erkan Demirkaya, Seza Ozen, Betul Sozeri, Nuray Aktay Ayaz, et al.
Rheumatology International, 2018
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Jaime de Inocencio, Jordi Anton, Inmaculada Calvo Penades, Pablo Mesa del Castillo Bermejo, et al.
Rheumatology International, 2018
The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Dirk Holzinger, Dirk Foell, Gerd Horneff, Ivan Foeldvari, et al.
Rheumatology International, 2018
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Miroslav Harjacek, Lovro Lamot, Mirta Lamot, Mandica Vidovic, et al.
Rheumatology International, 2018
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
For the Paediatric Rheumatology International Trials Organisation (PRINTO), Alessandro Consolaro, Francesca Bovis, Angela Pistorio, Rolando Cimaz, et al.
Rheumatology International, 2018
Recommendations for collaborative paediatric research including biobanking in Europe: A Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative
Jasmin B Kuemmerle-Deschner, Sandra Hansmann, Nico M Wulffraat, Sebastiaan J Vastert, Kristien Hens, et al.
Annals of the Rheumatic Diseases, 2018
Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDS): A Delphi study
Eldad Ben-Chetrit, Marco Gattorno, Ahmet Gul, Daniel L Kastner, Helen J Lachmann, et al.
Annals of the Rheumatic Diseases, 2018
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a multicentre, double-blind, randomised-withdrawal trial
Hermine I Brunner, Nicolino Ruperto, Nikolay Tzaribachev, Gerd Horneff, Vyacheslav G Chasnyk, et al.
Annals of the Rheumatic Diseases, 2018
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: Results of a phase 1, open-label, multicenter study
for the Pediatric Rheumatology International Trials Organization (PRINTO), Nicolino Ruperto, the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Zbigniew Zuber, et al.
Pediatric Rheumatology, 2017
A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry
Romina Gallizzi, Caterina Pidone, Luca Cantarini, Martina Finetti, Marco Cattalini, et al.
Pediatric Rheumatology, 2017
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects
Lisa G Rider, Nicolino Ruperto, Angela Pistorio, Brian Erman, Nastaran Bayat, et al.
Rheumatology United Kingdom, 2017
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry
for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Project, Riccardo Papa, Matteo Doglio, Helen J. Lachmann, Seza Ozen, et al.
Orphanet Journal of Rare Diseases, 2017
Extrapolation or controlled trials in paediatrics: The current dilemma
Nicolino Ruperto, Hermine I Brunner, Daniel J Lovell, Alberto Martini
Archives of Disease in Childhood, 2017
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Francesca Minoia, Francesca Bovis, Sergio Davì, Antonella Insalaco, Kai Lehmberg, et al.
Journal of Pediatrics, 2017
Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis
Paula Frid, Ellen Nordal, Francesca Bovis, Gabriella Giancane, Tore A. Larheim, et al.
Arthritis Care and Research, 2017
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Rohit Aggarwal, Lisa G Rider, Nicolino Ruperto, Nastaran Bayat, Brian Erman, et al.
Annals of the Rheumatic Diseases, 2017
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative
Lisa G Rider, Rohit Aggarwal, Angela Pistorio, Nastaran Bayat, Brian Erman, et al.
Annals of the Rheumatic Diseases, 2017
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Rohit Aggarwal, Lisa G. Rider, Nicolino Ruperto, Nastaran Bayat, Brian Erman, et al.
Arthritis and Rheumatology, 2017
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Lisa G. Rider, Rohit Aggarwal, Angela Pistorio, Nastaran Bayat, Brian Erman, et al.
Arthritis and Rheumatology, 2017
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: Challenges and opportunities
Timothy Beukelman, Janneke Anink, Lillemor Berntson, Ciaran Duffy, Justine A. Ellis, et al.
Pediatric Rheumatology, 2017
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial
Angelo Ravelli, Sergio Davì, Giulia Bracciolini, Angela Pistorio, Alessandro Consolaro, et al.
Lancet, 2017
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), Arndt H. Brachat, Alexei A. Grom, Nico Wulffraat, Hermine I. Brunner, et al.
Arthritis Research and Therapy, 2017
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
on behalf of the Italian Pediatric Rheumatology Study Group, Sara Verazza, Sergio Davì, Alessandro Consolaro, Francesca Bovis, et al.
Pediatric Rheumatology, 2016
Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial
Antonio Brucato, Massimo Imazio, Marco Gattorno, George Lazaros, Silvia Maestroni, et al.
JAMA Journal of the American Medical Association, 2016
Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: Pharmacokinetics, efficacy and safety
E. Solau-Gervais, D. Lovell, N. Ruperto, N. Tzaribachev, G. Vega-Cornejo, et al.
Revue Du Rhumatisme Edition Francaise, 2016
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry
Nienke M. ter Haar, Jerold Jeyaratnam, Helen J. Lachmann, Anna Simon, Paul A. Brogan, et al.
Arthritis and Rheumatology, 2016
The PRINTO juvenile dermatomyositis trial – Authors' reply
Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Simona Angioloni, Alberto Martini
Lancet, 2016
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis
Erkan Demirkaya, Stefano Lanni, Francesca Bovis, Roberta Galasso, Angelo Ravelli, et al.
Arthritis and Rheumatology, 2016
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis
Tamas Constantin, Ivan Foeldvari, Jelena Vojinovic, Gerd Horneff, Ruben Burgos-Vargas, et al.
Journal of Rheumatology, 2016
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Angelo Ravelli, Francesca Minoia, Sergio Davì, AnnaCarin Horne, Francesca Bovis, et al.
Arthritis and Rheumatology, 2016
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
Angelo Ravelli, Francesca Minoia, Sergio Davì, AnnaCarin Horne, Francesca Bovis, et al.
Annals of the Rheumatic Diseases, 2016
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial
Nicolino Ruperto, Angela Pistorio, Sheila Oliveira, Francesco Zulian, Ruben Cuttica, et al.
Lancet, 2016
Trial design and collaborative work in pediatric rheumatology
Alessandro Consolaro, Nicola Ruperto
Pediatric Rheumatology A Clinical Viewpoint, 2016
Biologic response modifiers in pediatric rheumatology
Alessandro Consolaro, Nicola Ruperto
Pediatric Rheumatology A Clinical Viewpoint, 2016
PROMs for juvenile idiopathic arthritis
Alessandro Consolaro, Stefano Lanni, Angelo Ravelli, Nicolino Ruperto
Patient Reported Outcome Measures in Rheumatic Diseases, 2016
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Canakinumab
Alexei A. Grom, Norman T. Ilowite, Virginia Pascual, Hermine I. Brunner, Alberto Martini, et al.
Arthritis and Rheumatology, 2016
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry
Erkan Demirkaya, Celal Saglam, Turker Turker, Isabelle Koné-Paut, Pat Woo, et al.
Journal of Rheumatology, 2016
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Angelo Ravelli, Francesca Minoia, Sergio Davì, AnnaCarin Horne, Francesca Bovis, et al.
Rmd Open, 2016
Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: A series of 136 patients from the Eurofever Registry
R Levy, L Gérard, J Kuemmerle-Deschner, H J Lachmann, I Koné-Paut, et al.
Annals of the Rheumatic Diseases, 2015
Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years
Daniel J. Lovell, Nicolino Ruperto, Richard Mouy, Eliana Paz, Nadina Rubio‐Pérez, et al.
Arthritis and Rheumatology, 2015
How experts on Autoinflammatory diseases classify Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical Adenitis (PFAPA): Preliminary results of the Eurofever Delphi survey
F Vanoni, S Federici, S Ozen, J Frenkel, H Lachmann, et al.
Pediatric Rheumatology, 2015
How experts on autoinflammatory diseases classify inherited periodic fevers: Preliminary results of the Eurofever Delphi Survey
S Federici, F Vanoni, S Ozen, J Frenkel, H Lachmann, et al.
Pediatric Rheumatology, 2015
Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
G Horneff, N Ruperto, H Brunner, P Quartier, T Constantin, et al.
Pediatric Rheumatology, 2015
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the Innovative Medicines Initiative ABIRISK consortium
ABIRISK Consortium, B Rup, M Pallardy, D Sikkema, T Albert, et al.
Clinical and Experimental Immunology, 2015
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Francesca Minoia, Sergio Davì, AnnaCarin Horne, Francesca Bovis, Erkan Demirkaya, et al.
Journal of Rheumatology, 2015
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: Results from a phase 3, randomised, double-blind withdrawal trial
Hermine I Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, et al.
Annals of the Rheumatic Diseases, 2015
Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers
Silvia Federici, Maria Pia Sormani, Seza Ozen, Helen J Lachmann, Gayane Amaryan, et al.
Annals of the Rheumatic Diseases, 2015
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from a phase iii trial
Fabrizio De Benedetti, Hermine Brunner, Nicolino Ruperto, Rayfel Schneider, Ricardo Xavier, et al.
Arthritis and Rheumatology, 2015
Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes
Maryam Piram, Isabelle Koné-Paut, Helen J Lachmann, Joost Frenkel, Seza Ozen, et al.
Annals of the Rheumatic Diseases, 2014
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: A series of 158 cases from the Eurofever/EUROTRAPS international registry
H J Lachmann, R Papa, K Gerhold, L Obici, I Touitou, et al.
Annals of the Rheumatic Diseases, 2014
Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three-Variable Juvenile Arthritis Disease Activity Score
Alessandro Consolaro, Giorgia Negro, Maria Chiara Gallo, Giulia Bracciolini, Cristina Ferrari, et al.
Arthritis Care and Research, 2014
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients
Francesca Minoia, Sergio Davì, AnnaCarin Horne, Erkan Demirkaya, Francesca Bovis, et al.
Arthritis and Rheumatology, 2014
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Sergio Davì, Francesca Minoia, Angela Pistorio, AnnaCarin Horne, Alessandro Consolaro, et al.
Arthritis and Rheumatology, 2014
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?
Stefano Lanni, Francesca Bovis, Francesca Magnaguagno, Angelo Ravelli, Stefania Viola, et al.
Pediatric Rheumatology, 2014
Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients
PRINTO, Alessandro Consolaro, Francesca Bovis, Ekaterina Alexeeva, Violeta Panaviene, et al.
Pediatric Rheumatology, 2014
Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis)
Marek Bohm, Maria Isabel Gonzalez Fernandez, Seza Ozen, Angela Pistorio, Pavla Dolezalova, et al.
Pediatric Rheumatology, 2014
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
Rina Mina, Marisa S Klein-Gitelman, Shannen Nelson, B Anne Eberhard, Gloria Higgins, et al.
Annals of the Rheumatic Diseases, 2014
Juvenile idiopathic arthritis and malignancy
N. Ruperto, A. Martini
Rheumatology United Kingdom, 2014
Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis
Gabriella Giancane, Silvia Pederzoli, Ximena Norambuena, Maka Ioseliani, Juliana Sato, et al.
Arthritis Care and Research, 2014
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score
Alessandro Consolaro, Nicolino Ruperto, Giulia Bracciolini, Alessia Frisina, Maria Chiara Gallo, et al.
Annals of the Rheumatic Diseases, 2014
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis
Clara Malattia, Maria Beatrice Damasio, Annalisa Madeo, Angela Pistorio, Anna Providenti, et al.
Annals of the Rheumatic Diseases, 2014
Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis
Friederike Rothmund, Joachim Gerss, Nicolino Ruperto, Jan Däbritz, Helmut Wittkowski, et al.
Arthritis Care and Research, 2014
Results from a multicentre international registry of Familial Mediterranean fever: Impact of environment on the expression of a monogenic disease in children
Seza Ozen, Erkan Demirkaya, Gayane Amaryan, Isabelle Koné-Paut, Adem Polat, et al.
Annals of the Rheumatic Diseases, 2014
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: Part 1 (week 12) of the CLIPPER study
Gerd Horneff, Ruben Burgos-Vargas, Tamas Constantin, Ivan Foeldvari, Jelena Vojinovic, et al.
Annals of the Rheumatic Diseases, 2014
Impact of the European paediatric legislation in paediatric rheumatology: Past, present and future
Nicolino Ruperto, Richard Vesely, Agnes Saint-Raymond, Alberto Martini
Annals of the Rheumatic Diseases, 2013
Advances from clinical trials in juvenile idiopathic arthritis
Daniel J. Lovell, Nicola Ruperto, Edward H. Giannini, Alberto Martini
Nature Reviews Rheumatology, 2013
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: An international multicentre PRINTO study
Paivi M Miettunen, Angela Pistorio, Elena Palmisani, Angelo Ravelli, Earl Silverman, et al.
Annals of the Rheumatic Diseases, 2013
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
Dragana Lazarevic, Angela Pistorio, Elena Palmisani, Paivi Miettunen, Angelo Ravelli, et al.
Annals of the Rheumatic Diseases, 2013
Treatment of autoinflammatory diseases: Results from the Eurofever Registry and a literature review
Nienke ter Haar, Helen Lachmann, Seza Özen, Pat Woo, Yosef Uziel, et al.
Annals of the Rheumatic Diseases, 2013
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis
C Malattia, A Consolaro, S Pederzoli, A Madeo, A Pistorio, et al.
Annals of the Rheumatic Diseases, 2013
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept
NICOLETTA SOLARI, ELENA PALMISANI, ALESSANDRO CONSOLARO, ANGELA PISTORIO, STEFANIA VIOLA, et al.
Journal of Rheumatology, 2013
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
Fabrizio De Benedetti, Hermine I. Brunner, Nicolino Ruperto, Andrew Kenwright, Stephen Wright, et al.
New England Journal of Medicine, 2012
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
Nicolino Ruperto, Hermine I. Brunner, Pierre Quartier, Tamás Constantin, Nico Wulffraat, et al.
New England Journal of Medicine, 2012
Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: A comparative study
Joachim Gerss, Johannes Roth, Dirk Holzinger, Nicolino Ruperto, Helmut Wittkowski, et al.
Annals of the Rheumatic Diseases, 2012
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study
for the Pediatric Rheumatology International Trials Organization (PRINTO), Alessandro Consolaro, Nicolino Ruperto, Giovanni Filocamo, Stefano Lanni, et al.
Pediatric Rheumatology, 2012
Classification criteria and diagnostic tests for vasculitides
NICOLINO RUPERTO, for the Paediatric Rheumatology International Trials Organisation (PRINTO)
Journal of Rheumatology, 2012
Performance of the birmingham vasculitis activity score and disease extent index in childhood vasculitides
Clinical and Experimental Rheumatology, 2012
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score
Alessandro Consolaro, Giulia Bracciolini, Nicolino Ruperto, Angela Pistorio, Silvia Magni‐Manzoni, et al.
Arthritis and Rheumatism, 2012
An international registry on autoinflammatory diseases: The Eurofever experience
Natasa Toplak, Joost Frenkel, Seza Ozen, Helen J Lachmann, Patricia Woo, et al.
Annals of the Rheumatic Diseases, 2012
Ethics bureaucracy: A significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases
Mats G Hansson, Marco Gattorno, Joanna Stjernschantz Forsberg, Nils Feltelius, Alberto Martini, et al.
Archives of Disease in Childhood, 2012
Parent and child acceptable symptom state in juvenile idiopathic arthritis
GIOVANNI FILOCAMO, ALESSANDRO CONSOLARO, BENEDETTA SCHIAPPAPIETRA, NICOLINO RUPERTO, ANGELA PISTORIO, et al.
Journal of Rheumatology, 2012
A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus
Marite Rygg, Angela Pistorio, Angelo Ravelli, Mohamad Maghnie, Natascia Di Iorgi, et al.
Annals of the Rheumatic Diseases, 2012
A European network of paediatric research at the European Medicines Agency (Enpr-EMA)
Nicolino Ruperto, Irmgard Eichler, Ralf Herold, Gilles Vassal, Carlo Giaquinto, et al.
Archives of Disease in Childhood, 2012
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features
Nicolino Ruperto, Pierre Quartier, Nico Wulffraat, Patricia Woo, Angelo Ravelli, et al.
Arthritis and Rheumatism, 2012
Henoch-Schöenlein Purpura
Nicolino Ruperto
Textbook of Clinical Pediatrics, 2012
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: Findings from an open-label treatment extension (Annals of the Rheumatic Diseases (2010) 69, 3 (585-587))
Annals of the Rheumatic Diseases, 2012
Current medical treatments for juvenile idiopathic arthritis
Nicolino Ruperto, Alberto Martini
Frontiers in Pharmacology, 2011
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians
Nicolino Ruperto, Luigi Carozzino, Roberto Jamone, Federico Freschi, Gianfranco Picollo, et al.
Italian Journal of Pediatrics, 2011
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating
Bianca Lattanzi, Alessandro Consolaro, Nicoletta Solari, Nicolino Ruperto, Alberto Martini, et al.
Arthritis Care and Research, 2011
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis.
Lisa G. Rider, Victoria P. Werth, Adam M. Huber, Helene Alexanderson, Anand Prahalad Rao, et al.
Arthritis Care and Research, 2011
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study
Rachana Hasija, Angela Pistorio, Angelo Ravelli, Erkan Demirkaya, Raju Khubchandani, et al.
Arthritis and Rheumatism, 2011
Emerging drugs to treat juvenile idiopathic arthritis
Nicolino Ruperto, Alberto Martini
Expert Opinion on Emerging Drugs, 2011
Reply
Timothy Beukelman, Randy Q. Cron, Nivedita M. Patkar, Kenneth G. Saag, Esi Morgan DeWitt, et al.
Arthritis Care and Research, 2011
Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis
Alessandro Consolaro, Nicolino Ruperto, Angela Pistorio, Bianca Lattanzi, Nicoletta Solari, et al.
Arthritis Care and Research, 2011
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis
Carol A. Wallace, Edward H. Giannini, Bin Huang, Lukasz Itert, Nicolino Ruperto, et al.
Arthritis Care and Research, 2011
Networking in paediatrics: The example of the Paediatric Rheumatology International Trials Organisation (PRINTO)
Nicolino Ruperto, Alberto Martini
Archives of Disease in Childhood, 2011
Criteria to define response to therapy in paediatric rheumatic diseases
for the Paediatric Rheumatology International Trials Organisation (PRINTO), Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Rachana Hasija, et al.
European Journal of Clinical Pharmacology, 2011
A new approach to clinical care of juvenile idiopathic arthritis: The juvenile arthritis multidimensional assessment report
GIOVANNI FILOCAMO, ALESSANDRO CONSOLARO, BENEDETTA SCHIAPPAPIETRA, SARA DALPRÀ, BIANCA LATTANZI, et al.
Journal of Rheumatology, 2011
The Eurofever Project: Towards better care for autoinflammatory diseases
on behalf of the Eurofever Project, Seza Ozen, Joost Frenkel, Nicola Ruperto, Marco Gattorno
European Journal of Pediatrics, 2011
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis
SERGIO DAVÌ, ALESSANDRO CONSOLARO, DINARA GUSEINOVA, ANGELA PISTORIO, NICOLINO RUPERTO, et al.
Journal of Rheumatology, 2011
International consensus for a definition of disease flare in lupus
N Ruperto, LM Hanrahan, GS Alarcón, HM Belmont, RL Brey, et al.
Lupus, 2011
Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis
Clara Malattia, Maria Beatrice Damasio, Angela Pistorio, Maka Ioseliani, Iris Vilca, et al.
Annals of the Rheumatic Diseases, 2011
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation (Annals of the Rheumatic Diseases (2010) 69, (790-797))
Annals of the Rheumatic Diseases, 2011
JIA, treatment and possible risk of malignancies
Nicolino Ruperto, Alberto Martini
Nature Reviews Rheumatology, 2011
Erratum: Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension (Annals of the Rheumatic Diseases (2010) 69 (718-722) DOI 10.1136/ard.2008.100354)
Annals of the Rheumatic Diseases, 2011
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.
Timothy Beukelman, Nivedita M. Patkar, Kenneth G. Saag, Sue Tolleson‐Rinehart, Randy Q. Cron, et al.
Arthritis Care Research, 2011
Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis
Angelo Ravelli, Giulia C. Varnier, Sheila Oliveira, Esteban Castell, Olga Arguedas, et al.
Arthritis and Rheumatism, 2011
Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis
Clinical and Experimental Rheumatology, 2011
Periodic fever syndromes in Eastern and Central European countries: Results of a pediatric multinational survey
Eastern/Central European autoinflammatory collaborating group for the Paediatric Rheumatology International Trials Organization (PRINTO) and Eurofever Project, Nataša Toplak, Pavla Dolezalovà, Tamas Constantin, Anna Sedivà, et al.
Pediatric Rheumatology, 2010
Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease
Clinical and Experimental Rheumatology, 2010
Needs in paediatric Rheumatology: The PRINTO perspective
Nicolino Ruperto
Pharmaceuticals Policy and Law, 2010
Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs
Nicolino Ruperto, Edward H. Giannini, Angela Pistorio, Hermine I. Brunner, Alberto Martini, et al.
Arthritis and Rheumatism, 2010
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: Analyses from a randomized, placebo-controlled trial
Sudha Visvanathan, Carrie Wagner, Joseph C Marini, Daniel J Lovell, Alberto Martini, et al.
Pediatric Rheumatology, 2010
Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis
GIOVANNI FILOCAMO, SERGIO DAVÌ, ANGELA PISTORIO, MARTA BERTAMINO, NICOLINO RUPERTO, et al.
Journal of Rheumatology, 2010
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis
Nicolino Ruperto, Daniel J. Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio‐Pérez, et al.
Arthritis and Rheumatism, 2010
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria
Seza Ozen, Angela Pistorio, Silvia M Iusan, Aysin Bakkaloglu, Troels Herlin, et al.
Annals of the Rheumatic Diseases, 2010
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation
Nicolino Ruperto, Seza Ozen, Angela Pistorio, Pavla Dolezalova, Paul Brogan, et al.
Annals of the Rheumatic Diseases, 2010
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission a randomized clinical trial
Dirk Foell
JAMA, 2010
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension
Nicolino Ruperto, Daniel J Lovell, Ruben Cuttica, Patricia Woo, Silvia Meiorin, et al.
Annals of the Rheumatic Diseases, 2010
A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: Initial validation in juvenile idiopathic arthritis
Giovanni Filocamo, Benedetta Schiappapietra, Marta Bertamino, Angela Pistorio, Nicolino Ruperto, et al.
Rheumatology, 2010
Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients
Angelo Ravelli, Lucia Trail, Cristina Ferrari, Nicolino Ruperto, Angela Pistorio, et al.
Arthritis Care and Research, 2010
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra
Loredana Lepore, Giulia Paloni, Roberta Caorsi, Maria Alessio, Donato Rigante, et al.
Journal of Pediatrics, 2010
Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?
C Saad-Magalhães, A Pistorio, A Ravelli, G Filocamo, S Viola, et al.
Annals of the Rheumatic Diseases, 2010
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: Analysis of the PRINTO methotrexate trial
Iris Vilca, Pablo Garcia Munitis, Angela Pistorio, Angelo Ravelli, Antonella Buoncompagni, et al.
Annals of the Rheumatic Diseases, 2010
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.
Nicolino Ruperto, Daniel J. Lovell, Tracy Li, Flavio Sztajnbok, Claudia Goldenstein‐Schainberg, et al.
Arthritis Care Research, 2010
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.
Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Lisa G. Rider, Clarissa Pilkington, et al.
Arthritis Care Research, 2010
Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients
Alessandro Parodi, Sergio Davì, Alejandra Beatriz Pringe, Angela Pistorio, Nicolino Ruperto, et al.
Arthritis and Rheumatism, 2009
Development and validation of a composite disease activity score for juvenile idiopathic arthritis
Alessandro Consolaro, Nicolino Ruperto, Anna Bazso, Angela Pistorio, Silvia Magni‐Manzoni, et al.
Arthritis Care and Research, 2009
Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis
Clinical and Experimental Rheumatology, 2009
Health-related quality of life of patients with juvenile dermatomyositis: results from the paediatric rheumatology international trials organisation multinational quality of life cohort study
Maria Teresa Apaz, Claudia Saad‐Magalhães, Angela Pistorio, Angelo Ravelli, Juliana de Oliveira sato, et al.
Arthritis Care and Research, 2009
Development and testing of reduced joint counts in juvenile idiopathic arthritis
ANNA BAZSO, ALESSANDRO CONSOLARO, NICOLINO RUPERTO, ANGELA PISTORIO, STEFANIA VIOLA, et al.
Journal of Rheumatology, 2009
The authors reply
New England Journal of Medicine, 2008
Assessing current outcomes of juvenile idiopathic arthritis: A cross-sectional study in a tertiary center sample
Nicoletta Solari, Stefania Viola, Angela Pistorio, Silvia Magni‐Manzoni, Rosa Vitale, et al.
Arthritis Care and Research, 2008
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
Daniel J. Lovell, Nicolino Ruperto, Steven Goodman, Andreas Reiff, Lawrence Jung, et al.
New England Journal of Medicine, 2008
Reply
Nicolino Ruperto, Angela Pistorio, Angelo Ravelli, Alberto Martini, Paediatric Rheumatology International Trials Organisation (PRINTO)
Arthritis Care and Research, 2008
Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis
Silvia Magni‐Manzoni, Nicolino Ruperto, Angela Pistorio, Elena Sala, Nicoletta Solari, et al.
Arthritis Care and Research, 2008
Validation of the childhood health assessment questionnaire in active juvenile systemic lupus erythematosus
Silvia Meiorin, Angela Pistorio, Angelo Ravelli, Silvia M. Iusan, Giovanni Filocamo, et al.
Arthritis Care and Research, 2008
Network in pediatric rheumatology: The example of the Pediatric Rheumatology International Trials Organization
Nicolino Ruperto, Alberto Martini
World Journal of Pediatrics, 2008
Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis
Clinical and Experimental Rheumatology, 2008
Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman
Nicolino Ruperto, Alberto Martini, Daniel J. Lovell, Edward H. Giannini
Arthritis and Rheumatism, 2008
Consensus procedures and their role in pediatric rheumatology
Nicolino Ruperto, Silvia Meiorin, Silvia Mirela Iusan, Angelo Ravelli, Angela Pistorio, et al.
Current Rheumatology Reports, 2008
Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis
A Céspedes-Cruz, R Gutiérrez-Suárez, A Pistorio, A Ravelli, A Loy, et al.
Annals of the Rheumatic Diseases, 2008
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study
Nicolino Ruperto, Angelo Ravelli, Angela Pistorio, Virginia Ferriani, Immaculada Calvo, et al.
Arthritis Care and Research, 2008
Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation.
Georgian Medical News, 2008
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
Nicolino Ruperto, Daniel J Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, et al.
Lancet, 2008
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis
Elena Palmisani, Nicoletta Solari, Angela Pistorio, Nicolino Ruperto, Clara Malattia, et al.
Pediatric Rheumatology, 2007
PRINTO (Pediatric Rheumatology INternational Trials Organization): From the part of the children with rheumatic diseases
Area Pediatrica, 2007
The cutaneous assessment tool: Development and reliability in juvenile idiopathic inflammatory myopathy
A. M. Huber, E. M. Dugan, P. A. Lachenbruch, B. M. Feldman, M. D. Perez, et al.
Rheumatology, 2007
Macrophage activation syndrome in juvenile systemic lupus erythematosus: An under-recognized complication?
A. Pringe, L. Trail, N. Ruperto, A. Buoncompagni, A. Loy, et al.
Lupus, 2007
The Paediatric Rheumatology International Trials Organization (PRINTO)
N. Ruperto, A. Bazso, A. Ravelli, C. Malattia, G. Filocamo, et al.
Lupus, 2007
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis
Angelo Ravelli, Maka Ioseliani, Ximena Norambuena, Juliana Sato, Angela Pistorio, et al.
Arthritis and Rheumatism, 2007
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis
Nicolino Ruperto, Daniel J. Lovell, Ruben Cuttica, Nick Wilkinson, Patricia Woo, et al.
Arthritis and Rheumatism, 2007
Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis
Giovanni Filocamo, Flavio Sztajnbok, Adriana Cespedes‐cruz, Silvia Magni‐Manzoni, Angela Pistorio, et al.
Arthritis Care and Research, 2007
Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis
Journal of Rheumatology, 2007
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against rheumatism provisional classification criteria for juvenile systemic sclerosis
Francesco Zulian, Patricia Woo, Balu H. Athreya, Ronald M. Laxer, Thomas A. Medsger, et al.
Arthritis Care and Research, 2007
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases?
Journal of Rheumatology, 2007
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study
Sheila Oliveira, Angelo Ravelli, Angela Pistorio, Esteban Castell, Clara Malattia, et al.
Arthritis Care and Research, 2007
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study
R. Gutierrez-Suarez, A. Pistorio, A. Cespedes Cruz, X. Norambuena, B. Flato, et al.
Rheumatology, 2007
Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis
F. Sztajnbok, D. L. Coronel-Martinez, A. Diaz-Maldonado, C. Novarini, A. Pistorio, et al.
Rheumatology, 2007
Reply [2]
Nicolino Ruperto, Angelo Ravelli, Alberto Martini
Arthritis Care and Research, 2006
Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus [5]
Nicolino Ruperto, Angelo Ravelli, Irccs G. Gaslini, Alberto Martini, Irccs G. Gaslini
Arthritis and Rheumatism, 2006
Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis
Federica Rossi, Fiorella Di Dia, Olivia Galipò, Angela Pistorio, Maura Valle, et al.
Arthritis Care and Research, 2006
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus
Raul Gutiérrez‐Suárez, Nicolino Ruperto, Roberto Gastaldi, Angela Pistorio, Enrico Felici, et al.
Arthritis and Rheumatism, 2006
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study
Clinical and Experimental Rheumatology, 2006
EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides
S Ozen, N Ruperto, M J Dillon, A Bagga, K Barron, et al.
Annals of the Rheumatic Diseases, 2006
The Pediatric Rheumatology International Trials Organization/American College of Rheumatology Provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement
Nicolino Ruperto, Angelo Ravelli, Sheila Oliveira, Maria Alessio, Dimitrina Mihaylova, et al.
Arthritis Care and Research, 2006
Clinical assessment in juvenile dermatomyositis
Angelo Ravelli, Nicolino Ruperto, Lucia Trail, Enrico Felici, Elena Sala, et al.
Autoimmunity, 2006
Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis
Pablo Garcia‐Munitis, Marcia Bandeira, Angela Pistorio, Silvia Magni‐Manzoni, Nicolino Ruperto, et al.
Arthritis Care and Research, 2006
Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patients' well-being in juvenile idiopathic arthritis
M. Bandeira, A. Falcone, A. Pistorio, N. Ruperto, S. Magni-Manzoni, et al.
Rheumatology, 2006
Consensus in pediatric rheumatology: Part II - Definition of clinical improvement in systemic lupus erythematosus and juvenile dermatomyositis
Revista Brasileira De Reumatologia, 2005
Consensus in pediatric rheumatology: Part I - Criteria definition of inactive disease and remission in juvenile idiopathic arthritis/juvenile rheumatoid arthritis
Revista Brasileira De Reumatologia, 2005
Outcome in juvenile onset systemic lupus erythematosus
Angelo Ravelli, Nicolino Ruperto, Alberto Martini
Current Opinion in Rheumatology, 2005
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies
Chester V. Oddis, Lisa G. Rider, Ann M. Reed, Nicolino Ruperto, Hermine I. Brunner, et al.
Arthritis and Rheumatism, 2005
Localized scleroderma in childhood is not just a skin disease
Francesco Zulian, Cristina Vallongo, Patricia Woo, Ricardo Russo, Nicolino Ruperto, et al.
Arthritis and Rheumatism, 2005
Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis
Stefania Viola, Enrico Felici, Silvia Magni‐Manzoni, Angela Pistorio, Antonella Buoncompagni, et al.
Arthritis and Rheumatism, 2005
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis
Clinical and Experimental Rheumatology, 2005
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis
C Moretti, S Viola, A Pistorio, S Magni-Manzoni, N Ruperto, et al.
Annals of the Rheumatic Diseases, 2005
A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short- and long-term efficacy and safety results
Nicolino Ruperto, Irina Nikishina, Evgueni D. Pachanov, Ynessa Shachbazian, Anne Marie Prieur, et al.
Arthritis and Rheumatism, 2005
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Angelo Ravelli, Silvia Magni-Manzoni, Angela Pistorio, Cristina Besana, Tiziana Foti, et al.
Journal of Pediatrics, 2005
The pediatric rheumatology international trials organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set
Nicolino Ruperto, Angelo Ravelli, Ruben Cuttica, Graciela Espada, Seza Ozen, et al.
Arthritis and Rheumatism, 2005
PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it
N Ruperto, P Garcia-Munitis, L Villa, M Pesce, A Aggarwal, et al.
Annals of the Rheumatic Diseases, 2005
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis
Journal of Rheumatology, 2004
International research networks in pediatric rheumatology: The PRINTO perspective
Nicolino Ruperto, Alberto Martini
Current Opinion in Rheumatology, 2004
Functional ability and physical and psychosocial well-being of hypermobile schoolchildren
Clinical and Experimental Rheumatology, 2004
International consensus on preliminary definitions of improvement in adult and juvenile myositis
Lisa G. Rider, Edward H. Giannini, Hermine I. Brunner, Nicola Ruperto, Laura James‐Newton, et al.
Arthritis and Rheumatism, 2004
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate
Nicolino Ruperto, Kevin J. Murray, Valeria Gerloni, Nico Wulffraat, Sheila Knupp Feitosa De Oliveira, et al.
Arthritis and Rheumatism, 2004
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage
Nicolino Ruperto, Silvia Buratti, Carolina Duarte‐Salazar, Angela Pistorio, Andreas Reiff, et al.
Arthritis Care and Research, 2004
International consensus outcome measures for patient with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
D. A. Isenberg, E. Allen, V. Farewell, M. R. Ehrenstein, M. G. Hanna, et al.
Rheumatology, 2004
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis
N. Ruperto
Rheumatology, 2003
Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis
Elena Tsitsami, Elena Bozzola, Silvia Magni‐Manzoni, Stefania Viola, Angela Pistorio, et al.
Arthritis Care and Research, 2003
Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study
Angelo Ravelli, Carolina Duarte‐Salazar, Silvia Buratti, Andreas Reiff, Bram Bernstein, et al.
Arthritis Care and Research, 2003
The Child Health Questionnaire (CHQ-PF50) studies: Sincere congratulations and a sincere plea for terminological accurary (multiple letters) [6]
Clinical and Experimental Rheumatology, 2002
The Hungarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Croatian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Danish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The European Spanish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Finnish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Swiss German and Swiss French versions of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Belgian-Flemish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Norwegian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Slovak version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Hebrew version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology
Clinical and Experimental Rheumatology, 2001
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Latvian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Austrian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis
Journal of Rheumatology, 2001
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis
A. Ravelli, S. Viola, D. Migliavacca, A. Pistorio, N. Ruperto, et al.
Rheumatology, 2001
The Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Chilean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Greek version of the Childhood Health Assessment Questionnaire(CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)
Clinical and Experimental Rheumatology, 2001
Use of unlabelled and off licence drugs in children
F A. I Riordan
BMJ, 2000
The importance of clinical trials for the paediatric rheumatic diseases: Organisation, methodological and ethical problems
Gaslini, 2000
Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis
Clinical and Experimental Rheumatology, 1999
Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis
Journal of Rheumatology, 1999
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement
Haematologica, 1999
Responsiveness of outcome measures in juvenile chronic arthritis
N Ruperto
Rheumatology, 1999
The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis
Angelo Ravelli, Stefania Viola, Daniela Migliavacca, Nicolino Ruperto, Angela Pistorio, et al.
Journal of Pediatrics, 1999
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus
Journal of Rheumatology, 1998
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate
Nicolino Ruperto, Angelo Ravelli, Fernanda Falcini, Loredana Lepore, Rosetta De Sanctis, et al.
Annals of the Rheumatic Diseases, 1998
Specially training and distribution of work effort among US American College of rheumatology members caring for children with rheumatic disease
Arthritis and Rheumatism, 1997
Longterm health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status
Journal of Rheumatology, 1997
Longterm health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome
Journal of Rheumatology, 1997
Clinically important change in treatment trials for juvenile rheumatoid arthritis [1]
Journal of Rheumatology, 1997
Correlation between conventional disease activity measures in juvenile chronic arthritis
Angelo Ravelli, Stefania Viola, Nicolino Ruperto, Barbara Corsi, Giuseppina Ballardini, et al.
Annals of the Rheumatic Diseases, 1997
Preliminary definition of improvement in juvenile arthritis
Edward H. Giannini, Nicolino Ruperto, Angelo Ravelli, Daniel J. Lovell, David T. Felson, et al.
Arthritis and Rheumatism, 1997
Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A phase I/II study
Journal of Rheumatology, 1996
Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis
Journal of Rheumatology, 1995
Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis
A. Ravelli, S. Viola, B. Ramenghi, G. Di Fuccia, N. Ruperto, et al.
Clinical Rheumatology, 1995
Chronic recurrent multifocal osteomyelitis with unusual features
A Ravelli, GL Marseglia, S Viola, N Ruperto, A Martini
Acta Pdiatrica, 1995
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis
A Ravelli, B Ramenghi, GDi Fuccia, N Ruperto, L Zonta, et al.
Acta Paediatrica International Journal of Paediatrics, 1994
Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis
F De Benedetti, M De Amici, L Aramini, N Ruperto, A Martini
Archives of Disease in Childhood, 1993
The Schönlein-Henoch syndrome with severe multisystemic involvement
Minerva Pediatrica, 1993

Nicolino Ruperto

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications